Back to top

oncology-screening: Archive

Zacks Equity Research

Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?

RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.

ZTSNegative Net Change ACADNegative Net Change RXRXNegative Net Change

Shaun Pruitt

3 Medical Stocks to Consider as Markets Take a Breather

These top medical stocks may be able to provide defensive safety after President Trump's tariff hikes and July's unfavorable jobs report led to a market selloff.

JNJNegative Net Change THCNegative Net Change CVSPositive Net Change

Shaun Pruitt

2 Highly Ranked Stocks to Consider After Q2 Earnings: CLS, EXEL

Investors looking for a momentum stock that could be in store for higher highs may want to consider Celestica (CLS), while those looking for a buy-the-dip target have an intriguing option with Exelixis (EXEL).

EXELPositive Net Change CLSNegative Net Change

Ahan Chakraborty

Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?

Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.

AZNNegative Net Change BMYPositive Net Change MRKPositive Net Change MRNANegative Net Change ABBVPositive Net Change

Ahan Chakraborty

Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?

Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.

SDGRNegative Net Change RLAYNegative Net Change RXRXNegative Net Change